Boothbay Fund Management’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Boothbay Fund Management’s Portfolio DCPH Stock Details DCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-30,236	Closed	-$426K	–	2181
2023 Q2	$426K	Hold	30,236	–	–	0.01%	1175
2023 Q1	$467K	Sell	30,236 -36,782	-55%	-$614K	0.01%	1282
2022 Q4	$1.1M	Sell	67,018 -18,271	-21%	-$297K	0.03%	853
2022 Q3	$1.58M	Buy	+85,289	New	+$1.34M	0.04%	673
2022 Q1	–	Sell	-21,563	Closed	-$211K	–	2611
2021 Q4	$211K	Buy	21,563 +13,720	+175%	+$258K	0.01%	1465
2021 Q3	$267K	Buy	7,843 +826	+12%	+$26.4K	0.01%	1393
2021 Q2	$257K	Buy	+7,017	New	+$272K	0.01%	1380
2019 Q1	–	Sell	-30,454	Closed	-$639K	–	911
2018 Q4	$639K	Buy	30,454 +17,902	+143%	+$440K	0.09%	222
2018 Q3	$486K	Buy	+12,552	New	+$464K	0.05%	371

Other funds holding DCPH

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Boothbay Fund Management's DCPH Position: Q3 2023 in Review

Boothbay Fund Management sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q3 2023, closing a stake of 30,236 shares — an estimated $426K sold.

Boothbay Fund Management first reported a position in DCPH in Q3 2018 and held it in 9 quarters. The position peaked at $1.58M in Q3 2022. 157 funds tracked by Wall St. Rank hold DCPH as of Q3 2023.

Boothbay Fund Management reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Boothbay Fund Management sold 30,236 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q3 2023, an estimated $426K.
Boothbay Fund Management first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2018 and held it in 9 quarters.
Boothbay Fund Management's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $1.58M in Q3 2022.
157 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q3 2023.

Based on Boothbay Fund Management's 13F filing for Q3 2023, filed 14 Nov 2023.